1392PDose-determination results from a phase Ib/II study of ceritinib (CER) + ribociclib (RIB) in ALK-positive (ALK+) non-small cell lung cancer (NSCLC)
Santoro, A, Su, W-C, Navarro, A, Simonelli, M, Yang, J C-H, Ardizzoni, A, Barlesi, F, Kang, J H, Didominick, S, Abdelhady, A, Goswami, B, Crystal, A, Felip, EVolume:
29
Journal:
Annals of Oncology
DOI:
10.1093/annonc/mdy292.015
Date:
October, 2018
File:
PDF, 91 KB
2018
File converter
More search results
More benefits 
